Evidence map›Paper›PMID 39308333›Full record

ArticleESC heart failure2025

Prognostic impact of being underweight in patients undergoing mitral TEER: The OCEAN-Mitral registry.

Ryosuke Higuchi, Masaki Izumo, Yuki Izumi, Mike Saji, Mitsuaki Isobe, Yoshihiro Akashi, Masanori Yamamoto, Masahiko Asami, Yusuke Enta, Masaki Nakashima and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ryosuke HiguchiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3312-9922
Masaki IzumoDivision of Cardiology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Yuki IzumiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mitsuaki IsobeDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Yoshihiro AkashiDivision of Cardiology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Masanori YamamotoDepartment of Cardiology, Nagoya Heart Center, Nagoya, Japan.
Masahiko AsamiDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Yusuke EntaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
Masaki NakashimaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
Shinichi ShiraiDivision of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.
Shingo MizunoDepartment of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan.
Yusuke WatanabeDepartment of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Makoto AmakiDepartment of Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Kazuhisa KodamaDivision of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Junichi YamaguchiDepartment of Cardiology, Tokyo Woman's Medical University, Tokyo, Japan.
Toru NaganumaDepartment of Cardiology, New Tokyo Hospital, Chiba, Japan.
Hiroki BotaDepartment of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Yohei OhnoDeparment of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Masahiro YamawakiDepartment of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan.
Hiroshi UenoSecond Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kazuki MizutaniDivision of Cardiology, Department of Medicine, Kindai University Faculty of Medicine, Osaka, Japan.
Shunsuke KuboDepartment of Cardiology, Kurashiki Central Hospital, Okayama, Japan.
Toshiaki OtsukaDepartment of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Kentaro HayashidaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
OCEAN‐Mitral Investigators

Funding

Abbott Medical JapanBoston Scientific CorporationDaiichi-SankyoEdwards LifesciencesMedtronic Japan
6 · The paper itself

Abstract

aimsMitral transcatheter edge-to-edge repair (M-TEER) is a valid treatment option for severe mitral regurgitation (MR), necessitating accurate risk stratification of M-TEER candidates for effective patient selection, optimal periprocedural care and improved long-term outcomes. The body mass index (BMI) is a simple and practical prognostic index, and the obesity paradox has been widely reported. METHODS AND

resultsBetween April 2018 and June 2021, 2149 patients undergoing M-TEER were registered in the prospective multicentre registry and classified into three groups: underweight (BMI < 18.5 kg/m

conclusionsUnderweight patients had the highest mortality rate after M-TEER. Comorbidities, residual MR, discharge disposition and underweight status were correlated with postprocedural outcome.

Indexed as

Cardiac CatheterizationHeart Valve Prosthesis ImplantationMitral ValveMitral Valve InsufficiencyRegistriesThinnessAgedBody Mass IndexFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesRisk Assessmentbody mass indexobesity paradoxoutcometranscatheter edge‐to‐edge repairunderweight

Identifiers

PMID39308333
PMCPMC11769672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.